Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rupert Bartsch

Showing results (181-190 of 228) with videos related to

Pageof 23
Sort By:
European Journal of Cancer (Oxford, England : 1990)|July 1, 2020
Hypothyroidism correlates with favourable survival prognosis in patients with brain metastatic cancerAnna S Berghoff, Christoph Wippel, Angelika M Starzer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2008
Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapyPeter Dubsky, Paul Sevelda, Raimund Jakesz, et al.
Journal of Psychosomatic Research|December 17, 2024
The myth of a cancer-specific temperament: An analysis of affective temperament in cancer patientsElisabeth L Zeilinger, Matthias Knefel, Andreas Erfurth, et al.
International Journal of Clinical and Health Psychology : IJCHP|September 4, 2023
The impact of COVID-19 and socioeconomic status on psychological distress in cancer patientsElisabeth Lucia Zeilinger, Matthias Knefel, Carmen Schneckenreiter, et al.
Future Oncology (London, England)|February 28, 2025
TUXEDO-4: phase II study of trastuzumab-deruxtecan in HER2-low breast cancer with new or progressing brain metastasesMaximilian Marhold, Marta Vaz Batista, Isabel Blancas, et al.
JCO Global Oncology|February 2, 2021
Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in OncologyConcetta Elisa Onesti, Marco Tagliamento, Giuseppe Curigliano, et al.
Journal of Translational Medicine|October 8, 2024
Monocyte subsets in breast cancer patients under treatment with aromatase inhibitor and mucin-1 cancer vaccineViktoria Knöbl, Lukas Maier, Stefan Grasl, et al.
ESMO Open|October 14, 2020
Thirteen-year analyses of medical oncology outpatient day clinic data: a changing fieldMaximilian Marhold, Thais Topakian, Hermine Agis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2017
Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast CancerChristian F Singer, Yen Y Tan, Florian Fitzal, et al.
The Lancet. Oncology|February 16, 2019
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trialSherene Loi, Anita Giobbie-Hurder, Andrea Gombos, et al.
Pageof 23

Showing results (181-190 of 228) with videos related to

Sort By:
Pageof 23
European Journal of Cancer (Oxford, England : 1990)|July 1, 2020
Hypothyroidism correlates with favourable survival prognosis in patients with brain metastatic cancerAnna S Berghoff, Christoph Wippel, Angelika M Starzer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2008
Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapyPeter Dubsky, Paul Sevelda, Raimund Jakesz, et al.
Journal of Psychosomatic Research|December 17, 2024
The myth of a cancer-specific temperament: An analysis of affective temperament in cancer patientsElisabeth L Zeilinger, Matthias Knefel, Andreas Erfurth, et al.
International Journal of Clinical and Health Psychology : IJCHP|September 4, 2023
The impact of COVID-19 and socioeconomic status on psychological distress in cancer patientsElisabeth Lucia Zeilinger, Matthias Knefel, Carmen Schneckenreiter, et al.
Future Oncology (London, England)|February 28, 2025
TUXEDO-4: phase II study of trastuzumab-deruxtecan in HER2-low breast cancer with new or progressing brain metastasesMaximilian Marhold, Marta Vaz Batista, Isabel Blancas, et al.
JCO Global Oncology|February 2, 2021
Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in OncologyConcetta Elisa Onesti, Marco Tagliamento, Giuseppe Curigliano, et al.
Journal of Translational Medicine|October 8, 2024
Monocyte subsets in breast cancer patients under treatment with aromatase inhibitor and mucin-1 cancer vaccineViktoria Knöbl, Lukas Maier, Stefan Grasl, et al.
ESMO Open|October 14, 2020
Thirteen-year analyses of medical oncology outpatient day clinic data: a changing fieldMaximilian Marhold, Thais Topakian, Hermine Agis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2017
Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast CancerChristian F Singer, Yen Y Tan, Florian Fitzal, et al.
The Lancet. Oncology|February 16, 2019
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trialSherene Loi, Anita Giobbie-Hurder, Andrea Gombos, et al.
Pageof 23